Citations (132)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Timothy J. Tse, Yajia Guo, Youn Young Shim, Sarah K. Purdy, Ji Hye Kim, Jae Youl Cho, Jane Alcorn & Martin J. T. Reaney. (2023) Availability of bioactive flax lignan from foods and supplements. Critical Reviews in Food Science and Nutrition 63:29, pages 9843-9858.
Read now
Read now
Oluwayemisi Esan, Adie Viljoen & Anthony S. Wierzbicki. (2022) Colesevelam – a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia. Expert Opinion on Pharmacotherapy 23:12, pages 1363-1370.
Read now
Read now
Yasamin Davatgaran Taghipour, Marziyeh Hajialyani, Rozita Naseri, Mahvash Hesari, Pantea Mohammadi, Azzurra Stefanucci, Adriano Mollica, Mohammad Hosein Farzaei & Mohammad Abdollahi. (2019) Nanoformulations of natural products for management of metabolic syndrome. International Journal of Nanomedicine 14, pages 5303-5321.
Read now
Read now
Claudia Stefanutti. (2014) Targeting MTP for the treatment of homozygous familial hypercholesterolemia. Clinical Lipidology 9:3, pages 369-381.
Read now
Read now
Binh An P Phan, Thomas D Dayspring & Peter P Toth. (2012) Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management 8, pages 415-427.
Read now
Read now
Hisashi Shinkai. (2012) Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vascular Health and Risk Management 8, pages 323-331.
Read now
Read now
PradeepK. Dhal, DiegoA. Gianolio & RobertJ. Miller. (2011) (Bio)polymeric Hydrogels as Therapeutic Agents. Journal of Macromolecular Science, Part A 48:12, pages 994-1003.
Read now
Read now
Hisashi Shinkai. (2009) Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Expert Opinion on Therapeutic Patents 19:9, pages 1229-1237.
Read now
Read now
Harold E Bays, David Neff, Joanne E Tomassini & Andrew M Tershakovec. (2008) Ezetimibe: cholesterol lowering and beyond. Expert Review of Cardiovascular Therapy 6:4, pages 447-470.
Read now
Read now
Harold E Bays, Ann P Tighe, Richard Sadovsky & Michael H Davidson. (2008) Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Review of Cardiovascular Therapy 6:3, pages 391-409.
Read now
Read now
Antonio Gaddi, AFG Cicero, FO Odoo, A Poli A & R Paoletti. (2007) Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vascular Health and Risk Management 3:6, pages 877-886.
Read now
Read now
Harold Bays & Peter H Jones. (2007) Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vascular Health and Risk Management 3:5, pages 733-742.
Read now
Read now
Harold E. Bays & David E. Cohen. (2007) Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Current Medical Research and Opinion 23:7, pages 1673-1684.
Read now
Read now
R.G. Elkin. (2007) Reducing shell egg cholesterol content. II. Review of approaches utilizing non-nutritive dietary factors or pharmacological agents and an examination of emerging strategies. World's Poultry Science Journal 63:1, pages 5-32.
Read now
Read now
Harold Bays, Lawrence Blonde & Robert Rosenson. (2006) Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. Expert Review of Cardiovascular Therapy 4:6, pages 871-895.
Read now
Read now
Grant H Skrepnek. (2005) Cost–effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. Expert Review of Pharmacoeconomics & Outcomes Research 5:5, pages 603-623.
Read now
Read now
Oriol Manuel, Rodolphe Thiébaut, Roger Darioli & Philip E Tarr. (2005) Treatment of dyslipidaemia in HIV-infected persons. Expert Opinion on Pharmacotherapy 6:10, pages 1619-1645.
Read now
Read now
Harold Bays, James McKenney & Michael Davidson. (2005) Torcetrapib/atorvastatin combination therapy. Expert Review of Cardiovascular Therapy 3:5, pages 789-820.
Read now
Read now
Harold Bays. (2005) Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Review of Cardiovascular Therapy 3:3, pages 393-404.
Read now
Read now
Mark E. McGovern. (2005) Taking aim at HDL-C. Postgraduate Medicine 117:4, pages 29-44.
Read now
Read now
Harold E Bays. (2004) Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Review of Cardiovascular Therapy 2:4, pages 485-501.
Read now
Read now
Articles from other publishers (111)
Ethan Alexander, Elizabeth Cristiano & John M. Miles. 2022. Precision Medicine in Diabetes. Precision Medicine in Diabetes
65
87
.
Tadashi Honda & Iwao Ojima. 2021. The Curious World of Fluorinated Molecules. The Curious World of Fluorinated Molecules
241
276
.
Min Kyoung Kang. 2021. Stroke Revisited: Dyslipidemia in Stroke. Stroke Revisited: Dyslipidemia in Stroke
91
101
.
K. A. Shemerovskii, V. N. Fedorets, P. V. Seliverstov & S. R. Bakaeva. (2020) Colorectal bradyarrhythmia syndrome as a predictor of metabolic syndrome. Experimental and Clinical Gastroenterology 183:11, pages 44-50.
Crossref
Crossref
Yuhong Luo, Cen Xie, Chad N. Brocker, Jie Fan, Xuan Wu, Lijin Feng, Qiong Wang, Jie Zhao, Dasheng Lu, Mayank Tandon, Maggie Cam, Kristopher W. Krausz, Weiwei Liu & Frank J. Gonzalez. (2019) Intestinal PPARα Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6. Gastroenterology 157:3, pages 744-759.e4.
Crossref
Crossref
Anik Boudreau, Allison J. Richard, Jasmine A. Burrell, William T. King, Ruth Dunn, Jean-Marc Schwarz, David M. Ribnicky, Jennifer Rood, J. Michael Salbaum & Jacqueline M. Stephens. (2018)
An ethanolic extract of
Artemisia scoparia
inhibits lipolysis in vivo and has antilipolytic effects on murine adipocytes in vitro
. American Journal of Physiology-Endocrinology and Metabolism 315:5, pages E1053-E1061.
Crossref
Crossref
Milisav CutovicMilica LazovicVesna Vukovic-DejanovicDejan NikolicIvana Petronic-MarkovicDragana Cirovic. (2017) Clinoptilolite for Treatment of Dyslipidemia: Preliminary Efficacy Study. The Journal of Alternative and Complementary Medicine 23:9, pages 738-744.
Crossref
Crossref
Abeer Anabtawi, Patrick M. Moriarty & John M. Miles. (2017) Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. Current Cardiology Reports 19:7.
Crossref
Crossref
T. Honda & I. Ojima. 2017. Modern Synthesis Processes and Reactivity of Fluorinated Compounds. Modern Synthesis Processes and Reactivity of Fluorinated Compounds
499
531
.
Lukáš Dobiaš, Monika Laššánová & Viera Kristová. (2016) Hypolipidemic drugs and their effect on endothelial function: a review of results of clinical trials. Klinická farmakologie a farmacie 30:2, pages 38-45.
Crossref
Crossref
Claire Huth, Étienne Pigeon, Marie-Ève Riou, Josée St-Onge, Hélène Arguin, Erick Couillard, Marie-Julie Dubois, André Marette, Angelo Tremblay, S. John Weisnagel, Michel Lacaille, Pascale Mauriège & Denis R. Joanisse. (2016) Fitness, adiposopathy, and adiposity are independent predictors of insulin sensitivity in middle-aged men without diabetes. Journal of Physiology and Biochemistry 72:3, pages 435-444.
Crossref
Crossref
David S. Small, Wei Zhang, Jane Royalty, Ellen A. Cannady, Delyn Downs, Demetrio Ortega & Jeffrey G. Suico. (2016) Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib. European Journal of Clinical Pharmacology 72:5, pages 563-572.
Crossref
Crossref
C. Lebherz. (2016) Aktuelle Lipidtherapie bei Diabetes mellitusLipid management in diabetes mellitus. Der Diabetologe 12:2, pages 80-87.
Crossref
Crossref
Sebnem Garip, Sevgi Haman Bayari, Mete Severcan, Sherif Abbas, Igor K. Lednev & Feride Severcan. (2016) Structural effects of simvastatin on rat liver tissue: Fourier transform infrared and Raman microspectroscopic studies. Journal of Biomedical Optics 21:2, pages 025008.
Crossref
Crossref
Harold E. Bays, Peter H. Jones, Terry A. Jacobson, David E. Cohen, Carl E. Orringer, Shanu Kothari, Dan E. Azagury, John Morton, Ninh T. Nguyen, Eric C. Westman, Deborah B. Horn, Wendy Scinta & Craig Primack. (2016) Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. Journal of Clinical Lipidology 10:1, pages 33-57.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
285
315
.
Marianne Andersen. (2015) The robustness of diagnostic tests for GH deficiency in adults. Growth Hormone & IGF Research 25:3, pages 108-114.
Crossref
Crossref
Hyun-Hwa Son, Shin Hye Kim, Ju-Yeon Moon, Bong Chul Chung, Mi Jung Park & Man Ho Choi. (2015) Serum sterol profiling reveals increased cholesterol biosynthesis in childhood obesity. The Journal of Steroid Biochemistry and Molecular Biology 149, pages 138-145.
Crossref
Crossref
Tomoyuki Ota, Hideki Ishii, Susumu Suzuki, Akihito Tanaka, Yohei Shibata, Yosuke Tatami, Shingo Harata, Yusaku Shimbo, Yohei Takayama, Yoshihiro Kawamura, Naohiro Osugi, Kengo Maeda, Takahisa Kondo & Toyoaki Murohara. (2015) Relation Between Paradoxical Decrease in High-Density Lipoprotein Cholesterol Levels After Statin Therapy and Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction. The American Journal of Cardiology 115:4, pages 411-416.
Crossref
Crossref
Claudia Stefanutti & Gilbert R. Thompson. (2014) Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances. Current Atherosclerosis Reports 17:1.
Crossref
Crossref
Yunpeng Qi, Changtao Jiang, Naoki Tanaka, Kristopher W. Krausz, Chad N. Brocker, Zhong-Ze Fang, Bryce X. Bredell, Yatrik M. Shah & Frank J. Gonzalez. (2014) PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate. American Journal of Physiology-Gastrointestinal and Liver Physiology 307:5, pages G564-G573.
Crossref
Crossref
Suowen Xu, Zhiping Liu, Yan Huang, Jianwen Chen, Shaorui Chen, Xiaoyan Shen, Heqing Huang & Peiqing Liu. (2014) Effectiveness of combination therapy of atorvastatin and non lipid-modifying tanshinone IIA from Danshen in a mouse model of atherosclerosis. International Journal of Cardiology 174:3, pages 878-880.
Crossref
Crossref
Joseph Vamecq, Mustapha Cherkaoui-Malki, Pierre Andreoletti & Norbert Latruffe. (2014) The human peroxisome in health and disease: The story of an oddity becoming a vital organelle. Biochimie 98, pages 4-15.
Crossref
Crossref
S. Kianbakht, B. Abasi & Fataneh Hashem Dabaghian. (2014)
Improved Lipid Profile in Hyperlipidemic Patients Taking
Vaccinium arctostaphylos
Fruit Hydroalcoholic Extract: A Randomized Double-Blind Placebo-Controlled Clinical Trial
. Phytotherapy Research 28:3, pages 432-436.
Crossref
Crossref
Dong-Mei Zhao, Wen-Yan Li, Yu-Fang Shi, Xu-Qiong Xiong, Shuai Song, Chen-Zhou Hao, Mao-Sheng Cheng & Jing-Kang Shen. (2014) Pharmacophore-based design, synthesis, and biological evaluation of novel 3-((3,4-dichlorophenyl)(4-substituted benzyl)amino) propanamides as cholesteryl ester transfer protein (CETP) inhibitors. Chinese Chemical Letters 25:2, pages 299-304.
Crossref
Crossref
S Friedrich, JJP Kastelein, D James, T Waterhouse, SE Nissen, SJ Nicholls & KA Krueger. (2014) The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins. CPT: Pharmacometrics & Systems Pharmacology 3:1, pages 1-9.
Crossref
Crossref
S. Kianbakht & F. Hashem Dabaghian. (2013) Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: A randomized placebo. Controlled clinical trial. Complementary Therapies in Medicine 21:5, pages 441-446.
Crossref
Crossref
Hong-Tao Liu, Hong-Wei He, Xiao-Guang Bai, Ju-Xian Wang, Chang-Liang Xu, Shi-Ying Cai, Rong-Guang Shao & Yu-Cheng Wang. (2013) Arylsulfonylamino-Benzanilides as Inhibitors of the Apical Sodium-Dependent Bile Salt Transporter (SLC10A2). Molecules 18:6, pages 6883-6897.
Crossref
Crossref
Kyriakos E. Kypreos, Spyridon Gkizas, Loukianos S. Rallidis & Iordanis Karagiannides. (2013) HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochemical Pharmacology 85:11, pages 1575-1578.
Crossref
Crossref
Yu Kataoka, Kiyoko Uno, Rishi Puri & Stephen J Nicholls. (2013)
Epanova
®
and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy
. Future Cardiology 9:2, pages 177-186.
Crossref
Crossref
Shengjun Fan, Qiang Geng, Zhenyu Pan, Xin Li, Lu Tie, Yan Pan & Xuejun Li. (2012) Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Systems Biology 6:1.
Crossref
Crossref
Ian Hamilton-Craig, Karam Maximilien Kostner, Stan Woodhouse & David Colquhoun. (2012) Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations. International Journal of Evidence-Based Healthcare 10:3, pages 181-190.
Crossref
Crossref
Wen-Yan Li, Xu-Qiong Xiong, Dong-Mei Zhao, Yu-Fang Shi, Zhi-Heng Yang, Chao Yu, Pei-Wei Fan, Mao-Sheng Cheng & Jing-Kang Shen. (2012) Quinoline-3-carboxamide Derivatives as Potential Cholesteryl Ester Transfer Protein Inhibitors. Molecules 17:5, pages 5497-5507.
Crossref
Crossref
Michael-Friedrich Boettcher, Roland Heinig, Carsten Schmeck, Christian Kohlsdorfer, Matthias Ludwig, Anja Schaefer, Sabine Gelfert-Peukert, Georg Wensing & Olaf Weber. (2012) Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. British Journal of Clinical Pharmacology 73:2, pages 210-218.
Crossref
Crossref
Stefan Oswald & Werner Siegmund. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
Ioanna Vallianou, Nikolaos Peroulis, Panayotis Pantazis & Margarita Hadzopoulou-Cladaras. (2011) Camphene, a Plant-Derived Monoterpene, Reduces Plasma Cholesterol and Triglycerides in Hyperlipidemic Rats Independently of HMG-CoA Reductase Activity. PLoS ONE 6:11, pages e20516.
Crossref
Crossref
Xavier Pintó & Manuel Zúñiga. (2011) Tratamiento de la hipercolesterolemia y prevención de las enfermedades cardiovasculares mediante la inhibición de la reabsorción de ácidos biliares con resincolestiramina. Clínica e Investigación en Arteriosclerosis 23, pages 9-16.
Crossref
Crossref
Alexandros Vakalopoulos, Carsten Schmeck, Michael Thutewohl, Volkhart Li, Hilmar Bischoff, Klemens Lustig, Olaf Weber, Holger Paulsen & Harry Elias. (2011) Chromanol derivatives—A novel class of CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 21:1, pages 488-491.
Crossref
Crossref
Antonio García-Ríos, Javier Delgado-Lista, Pablo Pérez Martínez, Francisco Fuentes-Jiménez, Francisco Pérez-Jiménez & José López-Miranda. (2011) Eficacia de las estatinas en el manejo de la dislipemia. Un paso adelante. Revista Española de Cardiología Suplementos 11, pages 14-20.
Crossref
Crossref
R. Mangat, S. Warnakula, Y. Wang, J.C. Russell, R. Uwiera, D.F. Vine & S.D. Proctor. (2010) Model of intestinal chylomicron over-production and Ezetimibe treatment: Impact on the retention of cholesterol in arterial vessels. Atherosclerosis Supplements 11:1, pages 17-24.
Crossref
Crossref
Eugene Y. Tan, Georgy Hartmann, Qing Chen, Antonio Pereira, Scott Bradley, George Doss, Andy Shiqiang Zhang, Jonathan Z. Ho, Matthew P. Braun, Dennis C. Dean, Wei Tang & Sanjeev Kumar. (2010) Pharmacokinetics, Metabolism, and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Rats and Rhesus Monkeys. Drug Metabolism and Disposition 38:3, pages 459-473.
Crossref
Crossref
Naisheng Bai, Kan He, Alvin Ibarra, Antoine Bily, Marc Roller, Xiaozhuo Chen & Ralph Rühl. (2009)
Iridoids from
Fraxinus excelsior
with Adipocyte Differentiation-Inhibitory and PPARα Activation Activity
. Journal of Natural Products 73:1, pages 2-6.
Crossref
Crossref
W. Sangkitikomol, T. Tencomnao & A. Rocejanasaroj. (2010) Effects of Thai black sticky rice extract on oxidative stress and lipid metabolism gene expression in HepG2 cells. Genetics and Molecular Research 9:4, pages 2086-2095.
Crossref
Crossref
Sean R. Pyper, Navin Viswakarma, Songtao Yu & Janardan K. Reddy. (2010) PPARα: Energy Combustion, Hypolipidemia, Inflammation and Cancer. Nuclear Receptor Signaling 8:1, pages nrs.08002.
Crossref
Crossref
Farhan Aslam, Attiya Haque, L. Veronica Lee & JoAnne Foody. (2009) Hyperlipidemia in Older Adults. Clinics in Geriatric Medicine 25:4, pages 591-606.
Crossref
Crossref
Haodan Yuan, Bo Feng, Ying Yu, Jonathan Chupka, Jenny Y. Zheng, Timothy G. Heath & Brian R. Bond. (2009) Renal Organic Anion Transporter-Mediated Drug-Drug Interaction between Gemcabene and Quinapril. Journal of Pharmacology and Experimental Therapeutics 330:1, pages 191-197.
Crossref
Crossref
Guy D. Eslick, Peter R.C. Howe, Caroline Smith, Ros Priest & Alan Bensoussan. (2009) Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. International Journal of Cardiology 136:1, pages 4-16.
Crossref
Crossref
Tara L. Dall & Harold Bays. (2009) Addressing Lipid Treatment Targets Beyond Cholesterol: A Role for Prescription Omega-3 Fatty Acid Therapy. Southern Medical Journal 102:4, pages 390-396.
Crossref
Crossref
Gee-Hong Kuo, Thomas Rano, Patricia Pelton, Keith T. Demarest, Alan C. Gibbs, William V. Murray, Bruce P. Damiano & Margery A. Connelly. (2009)
Design, Synthesis, and Biological Evaluation of (2
R
,α
S
)-3,4-Dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-α-(trifluoromethyl)-1(2
H
)-quinolineethanol as Potent and Orally Active Cholesteryl Ester Transfer Protein Inhibitor
. Journal of Medicinal Chemistry 52:6, pages 1768-1772.
Crossref
Crossref
Harold Bays. 2009. Clinical Lipidology. Clinical Lipidology
530
543
.
Xiaoming Jia, Yanfeng Chen, Jeffrey Zidichouski, Junzeng Zhang, Changhao Sun & Yanwen Wang. (2008) Co-administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats. Atherosclerosis 201:1, pages 101-107.
Crossref
Crossref
Z Huang, X Zhou, A C Nicholson, A M GottoJrJr, D P Hajjar & J Han. (2008) Activation of peroxisome proliferator-activated receptor-α in mice induces expression of the hepatic low-density lipoprotein receptor. British Journal of Pharmacology 155:4, pages 596-605.
Crossref
Crossref
Adriana Adameová, Mučaji Pavol, Švec Pavel, Nagy Milan, Faberová Viera & Kuželová Magdaléna. (2008) Effects of Ligustrum delavayanum Hariot. on cholesterol levels and arrhythmogenesis induced by myocardial ischaemia–reperfusion injury in diabetic-hypercholesterolaemic rats. Environmental Toxicology and Pharmacology 26:2, pages 255-258.
Crossref
Crossref
Nazzareno Ballatori, Fang Fang, Whitney V. Christian, Na Li & Christine L. Hammond. (2008) Ostα-Ostβ is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. American Journal of Physiology-Gastrointestinal and Liver Physiology 295:1, pages G179-G186.
Crossref
Crossref
Un Ju Jung, Claudia Torrejon, Ann P Tighe & Richard J Deckelbaum. (2008) n−3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects. The American Journal of Clinical Nutrition 87:6, pages 2003S-2009S.
Crossref
Crossref
Marie-Hélène Fouchet, Frédéric Donche, Christelle Martin, Anne Bouillot, Christophe Junot, Anne-Bénédicte Boullay, Florent Potvain, Sylvie Demaria Magny, Hervé Coste, Max Walker, Marc Issandou & Nérina Dodic. (2008) Design and evaluation of a novel series of 2,3-oxidosqualene cyclase inhibitors with low systemic exposure, relationship between pharmacokinetic properties and ocular toxicity. Bioorganic & Medicinal Chemistry 16:11, pages 6218-6232.
Crossref
Crossref
Jun Wang, Ah Siew Sim, Xing Li Wang, Chris Salonikas, Mary Moriatis, Daya Naidoo & David E.L. Wilcken. (2008) Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis 197:2, pages 853-859.
Crossref
Crossref
Stephen Hanessian, Sébastien Guesné, Ludivine Riber, Julien Marin, Alain Benoist, Philippe Mennecier, Alain Rupin, Tony J. Verbeuren & Guillaume De Nanteuil. (2008) Targeting ACE and ECE with dual acting inhibitors. Bioorganic & Medicinal Chemistry Letters 18:3, pages 1058-1062.
Crossref
Crossref
Olivier Potterat & Matthias Hamburger. 2008. Natural Compounds as Drugs Volume I. Natural Compounds as Drugs Volume I
45
118
.
Adriana Adameová, Táňa Ravingerová, Pavel Švec, Viera Faberová & Magdaléna Kuželová. (2007) The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:Cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic–hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. European Journal of Pharmacology 576:1-3, pages 114-121.
Crossref
Crossref
Rajesh Krishna, Matt S Anderson, Arthur J Bergman, Bo Jin, Marissa Fallon, Josee Cote, Kim Rosko, Cynthia Chavez-Eng, Ryan Lutz, Daniel M Bloomfield, Maria Gutierrez, James Doherty, Fredrick Bieberdorf, Jeffrey Chodakewitz, Keith M Gottesdiener & John A Wagner. (2007) Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. The Lancet 370:9603, pages 1907-1914.
Crossref
Crossref
Harold E Bays & Ronald B Goldberg. (2007) The ‘Forgotten’ Bile Acid Sequestrants: Is Now a Good Time to Remember?. American Journal of Therapeutics 14:6, pages 567-580.
Crossref
Crossref
C. A. KIRK, J. F. BOUCHER, S. J. SUNDERLAND & J. A. WREN. (2007) Influence of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on the digestibility of a dry expanded diet in adult dogs. Journal of Veterinary Pharmacology and Therapeutics 30:s1, pages 66-72.
Crossref
Crossref
Lan Shen, Yan Zhang, Aihua Wang, Ellen Sieber-McMaster, Xiaoli Chen, Patricia Pelton, Jun Z. Xu, Maria Yang, Peifang Zhu, Lubing Zhou, Michael Reuman, Zhiyong Hu, Ronald Russell, Alan C. Gibbs, Hamish Ross, Keith Demarest, William V. Murray & Gee-Hong Kuo. (2007) Synthesis and Identification of [1,2,4]Thiadiazole Derivatives as a New Series of Potent and Orally Active Dual Agonists of Peroxisome Proliferator-Activated Receptors α and δ. Journal of Medicinal Chemistry 50:16, pages 3954-3963.
Crossref
Crossref
William C. Cromwell, Harold E. Bays & Peter P. Toth. 2007. Markers in Cardiology. Markers in Cardiology
217
250
.
Jieli Chen, Xu Cui, Alex Zacharek, Hao Jiang, Cynthia Roberts, Chunling Zhang, Mei Lu, Alissa Kapke, Carolyn S. Feldkamp & Michael Chopp. (2007) Niaspan increases angiogenesis and improves functional recovery after stroke. Annals of Neurology 62:1, pages 49-58.
Crossref
Crossref
Rüdiger Siekmeier, Hubert Scharnagl, Gert M. Kostner, Tanja Grammer, Tatjana Stojakovic & Winfried März. (2007) Lipoprotein(a) – Struktur, Epidemiologie und Funktion / Lipoprotein(a) – structure, epidemiology and function. LaboratoriumsMedizin 31:3, pages 109-124.
Crossref
Crossref
Robert A. Hegele & Junko Oshima. (2007) Phenomics and lamins: From disease to therapy. Experimental Cell Research 313:10, pages 2134-2143.
Crossref
Crossref
Shigeru Nakano, Yoichi Inada, Hiroaki Masuzaki, Tomohiro Tanaka, Shintaro Yasue, Takako Ishii, Naoki Arai, Ken Ebihara, Kiminori Hosoda, Kazuyasu Maruyama, Yoshinobu Yamazaki, Nobuo Shibata & Kazuwa Nakao. (2007) Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. American Journal of Physiology-Endocrinology and Metabolism 292:4, pages E1213-E1222.
Crossref
Crossref
John R. Guyton & Harold E. Bays. (2007) Safety Considerations with Niacin Therapy. The American Journal of Cardiology 99:6, pages S22-S31.
Crossref
Crossref
Tatsuo Tanimoto. (2007) . Folia Pharmacologica Japonica 129:4, pages 267-270.
Crossref
Crossref
William C. Cromwell & James D. Otvos. 2007. Therapeutic Lipidology. Therapeutic Lipidology
321
347
.
Harold E. Bays. 2007. Therapeutic Lipidology. Therapeutic Lipidology
221
240
.
Liliane Michalik, Johan Auwerx, Joel P. Berger, V. Krishna Chatterjee, Christopher K. Glass, Frank J. Gonzalez, Paul A. Grimaldi, Takashi Kadowaki, Mitchell A. Lazar, Stephen O'Rahilly, Colin N. A. Palmer, Jorge Plutzky, Janardan K. Reddy, Bruce M. Spiegelman, Bart Staels & Walter Wahli. (2006) International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. Pharmacological Reviews 58:4, pages 726-741.
Crossref
Crossref
Michael H. DavidsonH. Daniel Yannicelli. (2006) New Concepts in Dyslipidemia in the Metabolic Syndrome and Diabetes. Metabolic Syndrome and Related Disorders 4:4, pages 299-314.
Crossref
Crossref
Stefano Bellosta, Rodolfo Paoletti & Alberto Corsini. 2006. Comprehensive Management of High Risk Cardiovascular Patients. Comprehensive Management of High Risk Cardiovascular Patients
389
408
.
Parveen Abidi, Wei Chen, Fredric B. Kraemer, Hai Li & Jingwen Liu. (2006) The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms. Journal of Lipid Research 47:10, pages 2134-2147.
Crossref
Crossref
Angels Fisas, Xavier Codony, Gonzalo Romero, Alberto Dordal, Jesus Giraldo, Ramon Mercé, Jörg Holenz, David Heal, Helmut Buschmann & Petrus Johan Pauwels. (2006)
Chronic 5-HT
6
receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats
. British Journal of Pharmacology 148:7, pages 973-983.
Crossref
Crossref
Marc Issandou. (2006) Pharmacological regulation of low density lipoprotein receptor expression: Current status and future developments. Pharmacology & Therapeutics 111:2, pages 424-433.
Crossref
Crossref
M. O. Weickert & A. F. H. Pfeiffer. (2006) Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 49:8, pages 1732-1741.
Crossref
Crossref
Alexandre Loktionov. 2006. Nutrient-Drug Interactions. Nutrient-Drug Interactions
31
61
.
Jean-Marie Brusq, Nicolas Ancellin, Pascal Grondin, Raphaelle Guillard, Sandrine Martin, Yannick Saintillan & Marc Issandou. (2006) Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. Journal of Lipid Research 47:6, pages 1281-1288.
Crossref
Crossref
Andrea Cignarella, Stefano Bellosta, Alberto Corsini & Chiara Bolego. (2006) Hypolipidemic therapy for the metabolic syndrome. Pharmacological Research 53:6, pages 492-500.
Crossref
Crossref
Scott M. Grundy. (2006) Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nature Reviews Drug Discovery 5:4, pages 295-309.
Crossref
Crossref
Harold Bays. (2006) Statin Safety: An Overview and Assessment of the Data—2005. The American Journal of Cardiology 97:8, pages S6-S26.
Crossref
Crossref
Xavier Pintó. (2006) Las estatinas, los hábitos de vida y el tratamiento de la hipercolesterolemia: los tiempos cambian y los criterios también. Medicina Clínica 126:6, pages 217-219.
Crossref
Crossref
Wei-Jia Kong, Jingwen Liu & Jian-Dong Jiang. (2005) Human low-density lipoprotein receptor gene and its regulation. Journal of Molecular Medicine 84:1, pages 29-36.
Crossref
Crossref
Alexander Tenenbaum, Michael Motro & Enrique Z Fisman. (2005) Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovascular Diabetology 4:1.
Crossref
Crossref
Devi Nair. (2016) Antiretroviral therapy-induced hyperlipidaemia. International Journal of STD & AIDS 16:1_suppl, pages 2-13.
Crossref
Crossref
Parveen AbidiYue ZhouJian-Dong JiangJingwen Liu. (2005) Extracellular Signal-Regulated Kinase–Dependent Stabilization of Hepatic Low-Density Lipoprotein Receptor mRNA by Herbal Medicine Berberine. Arteriosclerosis, Thrombosis, and Vascular Biology 25:10, pages 2170-2176.
Crossref
Crossref
Robert A. Hegele & Rebecca L. Pollex. (2005) Genetic and physiological insights into the metabolic syndrome. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 289:3, pages R663-R669.
Crossref
Crossref
Jonathan N. Bauman, Theunis C. Goosen, Meera Tugnait, Vincent Peterkin, Susan I. Hurst, Lee C. Menning, Mark Milad, Michael H. Court & J. Andrew Williams. (2005) UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition 33:9, pages 1349-1354.
Crossref
Crossref
Harold E. Bays & Mark E. McGovern. (2007) Time as a Variable With Niacin Extended‐Release/Lovastatin vs. Atorvastatin and Simvastatin. Preventive Cardiology 8:4, pages 226-233.
Crossref
Crossref
Weijia Kong, Parveen Abidi, Fredric B. Kraemer, Jian-Dong Jiang & Jingwen Liu. (2005) In vivo activities of cytokine oncostatin M in the regulation of plasma lipid levels. Journal of Lipid Research 46:6, pages 1163-1171.
Crossref
Crossref
Asim K. Duttaroy. (2005) Postprandial activation of hemostatic factors: Role of dietary fatty acids. Prostaglandins, Leukotrienes and Essential Fatty Acids 72:6, pages 381-391.
Crossref
Crossref
Joel P. Berger, Taro E. Akiyama & Peter T. Meinke. (2005) PPARs: therapeutic targets for metabolic disease. Trends in Pharmacological Sciences 26:5, pages 244-251.
Crossref
Crossref
Nicolas Venteclef, Raphaelle Guillard & Marc Issandou. (2005) The imidazoline-like drug S23515 affects lipid metabolism in hepatocyte by inhibiting the oxidosqualene:lanosterol cyclase activity. Biochemical Pharmacology 69:7, pages 1041-1048.
Crossref
Crossref
Lori Mosca. (2005) Management of dyslipidemia in women in the post-hormone therapy era. Journal of General Internal Medicine 20:3, pages 297-305.
Crossref
Crossref
Josep Maria Del Bas, Juan Fernández-Larrea, Mayte Blay, Anna Ardèvol, Maria Josepa Salvadó, Lluis Arola & Cinta Bladé. (2005) Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats. The FASEB Journal 19:3, pages 1-24.
Crossref
Crossref
Tom Hsun-Wei Huang, Bhavani Prasad Kota, Valentina Razmovski & Basil D. Roufogalis. (2005) Herbal or Natural Medicines as Modulators of Peroxisome Proliferator-Activated Receptors and Related Nuclear Receptors for Therapy of Metabolic Syndrome. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 96:1, pages 3-14.
Crossref
Crossref
Emilio Luengo Fernández, Beatriz Ordóñez Rubio, Clara Bergua Martínez & Martín Laclaustra Gimeno. (2005) Obesidad, dislipemia y síndrome metabólico. Revista Española de Cardiología Suplementos 5:4, pages 21D-29D.
Crossref
Crossref
Peter J. Sinclair. 2005. Annual Reports in Medicinal Chemistry Volume 40. Annual Reports in Medicinal Chemistry Volume 40
71
83
.
Richard L. Dunbar & Daniel J. Rader. (2005) Current drug options for raising HDL cholesterol. Current Treatment Options in Cardiovascular Medicine 7:1, pages 15-23.
Crossref
Crossref
David Brieger, S Benedict Freedman, Leonard Kritharides & Harry Lowe. 2004. High-Risk Atherosclerotic Plaques. High-Risk Atherosclerotic Plaques
164
202
.
Robert A. Hegele. (2004) Treatment of partial lipodystrophy: can the zebra teach us about the horse?. Drug Discovery Today: Disease Mechanisms 1:2, pages 195-203.
Crossref
Crossref
Emily S. van Aalst-Cohen, Mieke D. Trip, Maud N. Vissers, Jessica Rodenburg & John J.P. Kastelein. (2004) Clinical, diagnostic and therapeutic aspects of (inherited) hypercholesterolemia. Drug Discovery Today: Disease Mechanisms 1:2, pages 165-170.
Crossref
Crossref
Emma A. Meagher. (2004) Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story. Current Cardiology Reports 6:6, pages 457-463.
Crossref
Crossref
Jean-François Landrier, Charles Thomas, Jacques Grober, Hélène Duez, Frédéric Percevault, Maâmar Souidi, Christine Linard, Bart Staels & Philippe Besnard. (2004) Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor-α-dependent. Journal of Biological Chemistry 279:44, pages 45512-45518.
Crossref
Crossref
Richard L. Dunbar & Daniel J. Rader. (2004) Therapeutic strategies for the treatment of dyslipidemia. Drug Discovery Today: Therapeutic Strategies 1:2, pages 169-176.
Crossref
Crossref
Harold Bays. (2004) Commentary. Evidence-based Cardiovascular Medicine 8:2, pages 173-176.
Crossref
Crossref
F. Diz-Lois. (2004) El papel del bloqueo de la absorción intestinal del colesterol en el tratamiento de la hipercolesterolemia. Revista Clínica Española 204:10, pages 554-560.
Crossref
Crossref